# Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer

> **NCT03821792** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 60 (estimated)

## Conditions studied

- Metastatic Prostate Carcinoma
- Prostate Adenocarcinoma
- Prostate Carcinoma Metastatic in the Bone
- Stage IV Prostate Cancer AJCC v8
- Stage IVA Prostate Cancer AJCC v8
- Stage IVB Prostate Cancer AJCC v8

## Interventions

- **DRUG:** Abiraterone Acetate
- **DRUG:** Apalutamide
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT03821792
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-07-22
- **Primary completion:** 2026-10-11
- **Final completion:** 2026-10-11
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03821792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03821792, "Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03821792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*